Humanis, one of the fastest growing pharmaceutical companies from Turkey, has received great interest at the world's largest pharmaceutical fair 2023 CPHI Barcelona. Yunus Sancak, CEO of Humanis, said: "We are proud to contribute to our country as a rapidly growing and developing company, while our share in the world market is increasing. The fair is very important for us to express this capacity in the international arena, to meet with suppliers, product developers and companies from all over the world and to revitalise our negotiations for cooperation. We are happy to have met with an intense attention from the first day of the fair."
CPHI (International Exhibition and Conference on Pharmaceutical Ingredients Worldwide), which brings together pharmaceutical professionals and is one of the world's largest exhibitions, was held in Barcelona this year with an intense participation. Nearly 2 thousand companies from all over the world participated in the exhibition, bringing together professionals and leaders from many areas of the pharmaceutical industry, from production to marketing.
For 10 years, Humanis, which has been producing reliable healthcare solutions, attracted great interest at CPHI with its wide product portfolio and effective healthcare solutions. Humanis, which is the first company to export pharmaceuticals from Turkey to China and manufactures pharmaceuticals for many countries in Europe with GMP certificates from Canada, Russia and Germany, is shaping the future of the sector. Humanis, which is the production partner of many global companies thanks to its wide product portfolio, experienced personnel and state-of-the-art production facility, has managed to be one of the remarkable companies of the fair.
YUNUS SANCAK: “WE ARE PROUD TO CONTRIBUTE TO OUR COUNTRY”
Speaking about the fair, CEO Yunus Sancak said:
“CPHI brings together active organisations, members and leaders of the sector from all over the world. Our share in the world market is increasing. As a rapidly growing and developing company, we are proud to contribute to our country in this regard. The fair is very important in terms of explaining our capacity in the international arena, meeting with suppliers, product developers and companies from all over the world, conveying our potential face-to-face and revitalising our collaborative negotiations. We participated in the fair under the Humanis name for the first time, and we met with intense attention for three days.”
YUNUS SANCAK: “WE PROVED OUR EFFECTIVITY IN BOTH LOCAL AND NATIONAL MARKET”
Emphasising that very important steps have been taken for the development of the sector in Turkey, Yunus Sancak said, "Our sector is making more progress and receiving more investments with the increasing importance given to domestic pharmaceutical production. We are strengthening our export network every year with our facilities that produce at international standards and our experienced workforce. As Humanis, we are working to make significant contributions to our country and our sector with our large-scale investments, experienced personnel, innovative and courageous initiatives. Therefore, as a company that can shape the future of the sector and has proven its effectiveness in the local and national market, we have important responsibilities."
HUMANIS WILL EXPAND ITS PRODUCT PORTFOLIO UNTIL 2030
Humanis, which adopts a human-oriented health philosophy, exports to more than 25 countries on 3 continents. Yunus Sancak, who informed that "We aim to export 70 million dollars annually in 2030", said the following about the future vision of the company:
“In 2023, we became the first company from Turkey to export pharmaceuticals to China. In the near future, we aim to export pharmaceuticals first to the Gulf Countries and then to the USA. Up until 2030, we have initiated our studies and investments to produce in the fields of rare diseases, central nervous system diseases, diabetes, cardiology and oncology. We continue our efforts to provide health wherever there are people. Developing more than 100 molecules in our R&D centre with more than 70 scientists, we have become one of the 5 largest pharmaceutical R&D centres encouraged by the Ministry of Industry and Technology. In healthcare, we have managed to create significant differences in production with our innovative and agile approaches compared to many companies. Today, we employ more than 1,200 people with our human-oriented business models. We act within the framework of honest, fair, transparent and reliable principles. These principles, which make us who we are, form the basis of our human-oriented corporate culture.”
What is CPHI?
CPHI (International Exhibition and Conference on Pharmaceutical Ingredients), the world's most comprehensive pharmaceutical exhibition, each year brings together professionals from around the world who shape the future of the pharmaceutical industry. The fair, which was held in Barcelona, Spain this year, brought together more than 2 thousand companies operating in the pharmaceutical industry. Providing companies with the opportunity to introduce themselves and participate in meetings that will expand their cooperation, this year, panels were held on many important topics such as new generation approaches in biomanufacturing and developments in personalised treatment.
In 2010, the company started to serve as Pharmactive within the Saya Group and has been continuing its activities under the name Humanis since 2023. Humanis, which acts with a human-oriented approach at every step and produces with the understanding of 'Sustainable health for everyone', is a health company that makes significant contributions to both the sector and Turkey with its production facility and R&D centre established in Çerkezköy with an investment of 200 million dollars.
Humanis, which has proven its competence in the international market by establishing production partnerships with the world's largest global pharmaceutical companies, is committed to creating value for people and human life all over the world within the framework of innovative, reliable and ethical values. Humanis, which has an effective portfolio in many different therapeutic areas such as paediatrics, cardiology, pulmonology, otolaryngology, internal medicine, infection, gastroenterology, dermatology, physiotherapy and rehabilitation, orthopaedics and emergency, also offers products in the field of Consumer Health in order to maintain its human-oriented innovative health philosophy. Humanis works to protect a healthy future with the solutions provided in different treatment areas.